Business
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
- More than 3 million people in the US have severe hypertriglyceridemia - The CORE Phase 3 clinical study further expands Ionis' late-stage pipeline and is
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"- More than 3 million people in the US have severe hypertriglyceridemia\n - The CORE Phase 3 clinical study further expands Ionis' late-stage pipeline and is the second Phase 3 clinical study in Ionis' broad olezarsen development program\n - Olezarsen is one of Ionis' wholly owned medicines the company plans to commercialize\n\n\nCARLSBAD, Calif., Nov. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx. The CORE study is evaluating olezarsen in people with severe hypertriglyceridemia (triglyceride levels ≥ 500 mg/dL). Severe hypertriglyceridemia is a life-threatening condition associated with high levels of apoC-III and chylomicronemia, which lead to higher rates of acute pancreatitis, higher risk of cardiovascular disease, and has a high morbidity rate.\n\n \n \n \n \n \n \n\n \n\"Severe hypertriglyceridemia is a common condition that affects millions of people around the world, including more than 3 million in the US,\" said Sotirios \"Sam\" Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis. \"Initiating the CORE study is a major step in realizing the full potential of olezarsen to treat the range of conditions related to elevated triglycerides associated with high levels of the apoC-llI protein.\"\nOlezarsen is an investigational antisense medicine that uses Ionis' LIgand-Conjugated Antisense, or LICA, technology. It is designed to inhibit the production of apoC-III for patients who are at risk for cardiometabolic disease and acute pancreatitis due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. \nCORE is a global, double-blind, randomized, placebo-controlled, registrational, Phase 3 study in patients with severe hypertriglyceridemia. It is designed to compare olezarsen to placebo in patients with triglyceride levels equal to or greater than 500 mg/dL who are on the current available standard of care therapies for elevated triglycerides. The primary endpoint of the study is the percent change in fasting triglycerides from baseline at month 6. Secondary endpoints include: percent change from baseline in triglycerides...